These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 32198651)

  • 41. Combination Immunotherapy Development in Melanoma.
    Eggermont AMM; Crittenden M; Wargo J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
    Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
    [No Abstract]   [Full Text] [Related]  

  • 43. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
    Hanna TP; Nguyen P; Baetz T; Booth CM; Eisenhauer E
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):609-617. PubMed ID: 30196844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
    Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
    Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
    Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combinatorial Approaches to the Treatment of Advanced Melanoma.
    Munhoz RR; Postow MA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.
    Mandalà M; De Logu F; Merelli B; Nassini R; Massi D
    Lab Invest; 2017 Feb; 97(2):166-175. PubMed ID: 27991907
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
    Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
    J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma.
    Sierra-Davidson K; Boland GM
    Hematol Oncol Clin North Am; 2024 Oct; 38(5):953-971. PubMed ID: 39060118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [mmunotherapy of cutaneous melanoma - update 2022].
    Oláh J
    Magy Onkol; 2022 Jun; 66(2):119-124. PubMed ID: 35724388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
    Luke JJ
    Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
    Wood K; Luke JJ
    Curr Oncol Rep; 2016 Nov; 18(11):67. PubMed ID: 27613168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
    Girotti MR; Saturno G; Lorigan P; Marais R
    Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.